Story perspectives

Trump's Medicare Proposal Sparks Concerns Over Senior Benefits

1/29/2026

Summary

Trump's Medicare Proposal

U.S. President Donald Trump's administration proposed a Medicare Advantage pay increase for 2027 of less than 1%, far below the expected $25 billion boost.
Insurers say the small increase could lead to higher premiums and reduced benefits for seniors.
The proposal aims to address overpayments tied to upcoding that have inflated costs.
Final payment-rate decisions are expected in early April 2026.

Summary

Trump's Drug Negotiations

The Trump administration is implementing its "most favored nation" pricing system while negotiating Medicare drug prices under the Inflation Reduction Act (IRA).
The Centers for Medicare & Medicaid Services announced 15 high-spend medications, including GSK's Anoro Ellipta and AbbVie's Botox, for price negotiations this year.
These drugs represented $27 billion in Medicare spending from November 2024 to October 2025, with new prices effective in early 2028.
Drugmakers must decide by the end of February 2024 whether to participate in the negotiations.

Summary

Trump's Medicare Rates

The U.S. President Donald Trump administration proposed flat Medicare Advantage payment rates for 2027, with a 0.09% increase by CMS below expectations.
Clover Health Investments Corp's stock fell 5.62% on the news.
Analysts say the risk-adjustment rules and small rise could force Clover to absorb costs or cut benefits.
The stock has fallen 48.70% over the past year, and Clover's next earnings report is scheduled for February 26.

1 of 3

Trump's Medicare Proposal

U.S. President Donald Trump's administration proposed a Medicare Advantage pay increase for 2027 of less than 1%, far below the expected $25 billion boost.
Insurers say the small increase could lead to higher premiums and reduced benefits for seniors.
The proposal aims to address overpayments tied to upcoding that have inflated costs.
Final payment-rate decisions are expected in early April 2026.

1 / 3